| 标题 |
SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes
在无糖尿病肥胖个体中进行的索马鲁肽和蛋白尿减少试验
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 | Brief Summary Study to assess the effects of weekly subcutaneous administration of the GLP1-RA semaglutide 2.4mg on kidney function parameters in obese/overweight individuals at high risk of CKD progression. Detailed Description Glucagon Like Peptide 1 Receptor Agonist (GLP1-RA) therapies have been introduced as antidiabetic drugs. In addition, GLP1-RA therapies reduce body weight, in patients with and without diabetes, without inducing hypoglycemia. Moreover, GLP1-RA reduce albuminuria in patients with type 2 diabetes, and liraglutide and semaglutide have been shown to improve various risk markers of CKD progression in non-diabetic obese individuals. It is therefore likely that these agents delay progression of kidney function decline in high risk obese/overweight, non-diabetic individuals. |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
浮游
changping
zcl
eric888
LPPQBB
小青椒
Smar_zcl
嘻嘻哈哈
Criminology34
chenqiumu
tuanheqi
GingerF
my
菠菜
star
xxfsx
子车茗
LaTeXer
aldehyde
Mic
laber
leaolf
虎皮猫大人
ccm
皖公网安备34019202002308
